# A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct06559722` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06559722](<https://clinicaltrials.gov/study/NCT06559722>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06559722

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 510 participants.

## Technical summary

Registry record NCT06559722. Randomized; no masking; primary purpose treatment. Start 2024-08 (anticipated); primary completion 2025-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 510 participants (planned count; ClinicalTrials.gov record NCT06559722, source copy `cardio:ctgov-nct06559722-2024-08-19`, retrieved 2026-10-26)
- Planned start: 2024-08 (anticipated) (ClinicalTrials.gov record NCT06559722, source copy `cardio:ctgov-nct06559722-2024-08-19`, retrieved 2026-10-26)
- Primary completion: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06559722, source copy `cardio:ctgov-nct06559722-2024-08-19`, retrieved 2026-10-26)
- Completion: 2026-02 (anticipated) (ClinicalTrials.gov record NCT06559722, source copy `cardio:ctgov-nct06559722-2024-08-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06559722-2024-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin Degludec/liraglutide Injection
- Intervention (Drug): XULTOPHY®
- Lead sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 1dbbf00b6e571c881c2438c0869d146e7f1b6a71dc873c16a6d6e7ac229b3244
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
